The SCRIM score: a clinical tool for cancer risk-stratification in patients with idiopathic inflammatory myopathy
Authors' conclusion
The SCRIM score precisely stratified the risk of myositis-associated cancer for patients with IIM, which can be an important basis for establishing an evidence-based screening cancer strategy.
Study context
- Population
- Patients with idiopathic inflammatory myopathy (IIM) from four independent cohorts in South Korea62 with myositis-associated cancer
- Participants
- 481 patients
- Comparison
- SCRIM score risk groups vs age-matched general population
- Outcome
- Myositis-associated cancer (cancer within 3 years before or after IIM diagnosis)
Methodological detailsmulticentre (four independent cohorts), Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression, conditional inference tree cut-off
- Multicentre (four independent cohorts)
- LASSO logistic regression
- Conditional inference tree cut-off
Performance
As reported in the abstract
Myositis-associated cancer: SCRIM score performance and risk-group incidence vs general population
| Test or model | Standardized incidence ratio (SIR) |
|---|---|
| Low-risk | 0.79 |
| Intermediate-risk | 2.28 |
| High-risk | 15.30 |
Standardized incidence ratio (SIR)
Low-risk0.79
Intermediate-risk2.28
High-risk15.30
- SCRIM score AUROC
- 0.852 (95% CI 0.796-0.907)
Further findings
Prevalence of myositis-associated cancer
- Myositis-associated cancer in study population (n = 62)
- 12.9%
Predictors selected by LASSO
- Higher risk: older age, male sex, current smoking, DM, anti-TIF1γ
- Lower risk: anti-synthetase syndrome, overlap myositis, arthritis, ILD
Original publication
The SCRIM score: a clinical tool for cancer risk-stratification in patients with idiopathic inflammatory myopathy. Arthritis Res Ther. Published 4 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →